Background: Autoimmune hepatitis (AIH) is a relatively rare disease that can develop regardless of age or ethnicity. However, its clinical features differ between eastern and western populations due to several heterogeneous genetic and environmental factors. We herein report the clinical characteristics of AIH patients in East Asia, Southeast Asia, and South Asia. Summary and Key Messages: The prevalence of AIH in eastern countries is considered to be lower than in western countries. Although a few young patients with type 2 AIH have been observed in South Asia, most patients in Asia are middle-aged women with type 1 AIH who respond well to steroid-based immunosuppressive therapy. Human leukocyte antigen DR4 is suggested to be an influential factor in the genetic background of AIH patients in Asia, particularly in East Asia. Notably, AIH may be induced by some societal- or culture-associated medicines, including herbal medicines. The IAIHG (International Autoimmune Hepatitis Group) scoring systems are generally accepted as the standard diagnostic methods for AIH in Asian countries. The results of repeated nationwide surveys in Japan suggest that the clinical features of AIH patients in East Asia are changing, with IgG levels and rates of anti-nuclear antibody positivity decreasing.

Keywords:
Autoimmune hepatitis, Prevalence, East Asia, Human leukocyte antigen DR4, Herbal medicines
1.
Heneghan MA, Yeoman AD, Verma S, Smith AD, Longhi MS: Lancet 2013;382:1433-1444.
2.
Wang Q, Yang F, Miao Q, Krawitt EL, Gershwin ME, Ma X: The clinical phenotypes of autoimmune hepatitis: a comprehensive review. J Autoimmun 2016;66:98-107.
3.
European Association for the Study of the Liver: EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol 2015;63:971-1004.
4.
Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM; American Association for the Study of Liver Diseases: Diagnosis and management of autoimmune hepatitis. Hepatology 2010;51:2193-2213.
5.
Casal Moura M, Liberal R, Cardoso H, Horta E, Vale AM, Macedo G: Management of autoimmune hepatitis: focus on pharmacologic treatments beyond corticosteroids. World J Hepatol 2014;6:410-418.
6.
Sahebjam F, Vierling JM: Autoimmune hepatitis. Front Med 2015;9:187-219.
7.
Yang F, Wang Q, Bian Z, Ren LL, Jia J, Ma X: Autoimmune hepatitis: east meets west. J Gastroenterol Hepatol 2015;30:1230-1236.
8.
Tanaka A, Ma X, Yokosuka O, Weltman M, You H, Amarapurkar DN, Kim YJ, Abbas Z, Payawal DA, Chang ML, Efe C, Ozaslan E, Abe M, Mitchell-Thain R, Zeniya M, Han KH, Vierling JM, Takikawa H: Autoimmune liver diseases in the Asia-Pacific region: proceedings of APASL symposium on AIH and PBC 2016. Hepatol Int 2016;10:909-915.
9.
Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T: A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 2013;14:1212-1218.
10.
Zamani MR, Aslani S, Salmaninejad A, Javan MR, Rezaei N. PD-1/PD-L and autoimmunity: a growing relationship. Cell Immunol 2016;310:27-41.
11.
Nakamoto N, Kaplan DE, Coleclough J, Li Y, Valiga ME, Kaminski M, Shaked A, Olthoff K, Gostick E, Price DA, Freeman GJ, Wherry EJ, Chang KM: Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology 2008;134:1927-1937.
12.
Callahan MK, Postow MA, Wolchok JD: Targeting T cell co-receptors for cancer therapy. Immunity 2016;44:1069-1078.
13.
Monna T, Kuroki T, Yamamoto S: Autoimmune hepatitis: the present status in Japan. Gastroenterol Jpn 1985;20:260-272.
14.
Onji M, Nonaka T, Horiike N, Moriwaki H, Muto Y, Ohta Y: Present status of autoimmune hepatitis in Japan. Gastroenterol Jpn 1993;28(suppl 4):134-138.
15.
Toda G, Zeniya M, Watanabe F, Imawari M, Kiyosawa K, Nishioka M, Tsuji T, Omata M: Present status of autoimmune hepatitis in Japan - correlating the characteristics with international criteria in an area with a high rate of HCV infection. Japanese National Study Group of Autoimmune Hepatitis. J Hepatol 1997;26:1207-1212.
16.
Abe M, Mashiba T, Zeniya M, Yamamoto K, Onji M, Tsubouchi H; Autoimmune Hepatitis Study Group-Subgroup of the Intractable Hepato-Biliary Disease Study Group in Japan: Present status of autoimmune hepatitis in Japan: a nationwide survey. J Gastroenterol 2011;46:1136-1141.
17.
Grønbæk L, Vilstrup H, Jepsen P: Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol 2014;60:612-617.
18.
Hurlburt KJ, McMahon BJ, Deubner H, Hsu-Trawinski B, Williams JL, Kowdley KV: Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol 2002;97:2402-2407.
19.
Ngu JH, Bechly K, Chapman BA, Burt MJ, Barclay ML, Gearry RB, Stedman CA: Population-based epidemiology study of autoimmune hepatitis: a disease of older women? J Gastroenterol Hepatol 2010;25:1681-1686.
20.
Haider AS, Kaye G, Thomson A: Autoimmune hepatitis in a demographically isolated area of Australia. Intern Med J 2010;40:281-285.
21.
Lee YM, Teo EK, Ng TM, Khor C, Fock KM: Autoimmune hepatitis in Singapore: a rare syndrome affecting middle-aged women. J Gastroenterol Hepatol 2001;16:1384-1389.
22.
Jalihal A, Telisinghe PU, Chong VH: Profiles of autoimmune hepatitis in Brunei Darussalam. Hepatobiliary Pancreat Dis Int 2009;8:602-607.
23.
Koay LB, Lin CY, Tsai SL, Lee C, Lin CN, Sheu MJ, Kuo HT, Sun CS: Type 1 autoimmune hepatitis in Taiwan: diagnosis using the revised criteria of the International Autoimmune Hepatitis Group. Dig Dis Sci 2006;51:1978-1984.
24.
Kim BH, Kim YJ, Jeong SH, Tak WY, Ahn SH, Lee YJ, Jung EU, Lee JI, Yeon JE, Hwang JS, Um SH, Seo YS, Kim YS, Song BC, Kim JH, Jung YK, Park CK, Kim KA, Min HJ, Cho EY, Lee ES, Kwon SY, Chae HB, Kim DJ, Shin SR: Clinical features of autoimmune hepatitis and comparison of two diagnostic criteria in Korea: a nationwide, multicenter study. J Gastroenterol Hepatol 2013;28:128-134.
25.
Wang Q, Selmi C, Zhou X, Qiu D, Li Z, Miao Q, Chen X, Wang J, Krawitt EL, Gershwin ME, Han Y, Ma X: Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis. J Autoimmun 2013;41:140-145.
26.
Amarapurkar D, Dharod M, Amarapurkar A: Autoimmune hepatitis in India: single tertiary referral centre experience. Trop Gastroenterol 2015;36:36-45.
27.
Hassan N, Siddiqui AR, Abbas Z, Hassan SM, Soomro GB, Mubarak M, Anis S, Muzaffar R, Zafar MN: Clinical profile and HLA typing of autoimmune hepatitis from Pakistan. Hepat Mon 2013;13:e13598.
28.
Low AS, Tan M, Garcia A, Aw M, Quak SH: Childhood autoimmune hepatitis in a paediatric unit of a tertiary care hospital. Singapore Med J 2014;55:648-651.
29.
Hoeroldt B, McFarlane E, Dube A, Basumani P, Karajeh M, Campbell MJ, Gleeson D: Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology 2011;140:1980-1989.
30.
Muratori P, Granito A, Quarneti C, Ferri S, Menichella R, Cassani F, Pappas G, Bianchi FB, Lenzi M, Muratori L: Autoimmune hepatitis in Italy: the Bologna experience. J Hepatol 2009;50:1210-1218.
31.
Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ: Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005;42:53-62.
32.
Gupta R, Agarwal SR, Jain M, Malhotra V, Sarin SK: Autoimmune hepatitis in the Indian subcontinent: 7 years experience. J Gastroenterol Hepatol 2001;16:1144-1148.
33.
Li JZ, Absher DM, Tang H, Southwick AM, Casto AM, Ramachandran S, Cann HM, Barsh GS, Feldman M, Cavalli-Sforza LL, Myers RM: Worldwide human relationships inferred from genome-wide patterns of variation. Science 2008;319:1100-1104.
34.
Doherty DG, Donaldson PT, Underhill JA, Farrant JM, Duthie A, Mieli-Vergani G, McFarlane IG, Johnson PJ, Eddleston AL, Mowat AP, Williams R: Allelic sequence variation in the HLA class II genes and protein in patients with autoimmune hepatitis. Hepatology 1994;19:609-615.
35.
Zeniya M, Takahashi H: Characteristics of autoimmune hepatitis in the Asia-Pacific Region: historical review. Hepatol Int 2012;6:342-349.
36.
de Boer YS, van Gerven NM, Zwiers A, Verwer BJ, van Hoek B, van Erpecum KJ, Beuers U, van Buuren HR, Drenth JP, den Ouden JW, Verdonk RC, Koek GH, Brouwer JT, Guichelaar MM, Vrolijk JM, Kraal G, Mulder CJ, van Nieuwkerk CM, Fischer J, Berg T, Stickel F, Sarrazin C, Schramm C, Lohse AW, Weiler-Normann C, Lerch MM, Nauck M, Völzke H, Homuth G, Bloemena E, Verspaget HW, Kumar V, Zhernakova A, Wijmenga C, Franke L, Bouma G; Dutch Autoimmune Hepatitis Study Group; LifeLines Cohort Study; Study of Health in Pomerania: Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology 2014;147:443-452.e5.
37.
Teufel A, Wörns M, Weinmann A, Centner C, Piendl A, Lohse AW, Galle PR, Kanzler S: Genetic association of autoimmune hepatitis and human leucocyte antigen in German patients. World J Gastroenterol 2006;12:5513-5516.
38.
Minuk GY, Liu S, Kaita K, Wong S, Renner E, Rempel J, Uhanova J: Autoimmune hepatitis in a North American Aboriginal/First Nations population. Can J Gastroenterol 2008;22:829-834.
39.
Lim YS, Oh HB, Choi SE, Kwon OJ, Heo YS, Lee HC, Suh DJ: Susceptibility to type 1 autoimmune hepatitis is associated with shared amino acid sequences at positions 70-74 of the HLA-DRB1 molecule. J Hepatol 2008;48:133-139.
40.
Tanwandee T, Wanichapol S, Vejbaesya S, Chainuvati S, Chotiyaputta W: Association between HLA class II alleles and autoimmune hepatitis type 1 in Thai patients. J Med Assoc Thai 2006;89(suppl 5):S73-S78.
41.
Vento S, Garofano T, Dolci L, Di Perri G, Concia E, Bassetti D: Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet 1991;337:1183-1187.
42.
Michalska Z, Stalke P, Witczak-Malinowska K, Lakomy EA, Sikorska K, Radowska D, Stolarczyk J, Trocha H: Autoimmune reactions in HBV and HCV. Med Sci Monit 2001;7(suppl 1):175-180.
43.
Vento S, Cainelli F, Renzini C, Concia E: Autoimmune hepatitis type 2 induced by HCV and persisting after viral clearance. Lancet 1997;350:1298-1299.
44.
van Gerven NM, van der Eijk AA, Pas SD, Zaaijer HL, de Boer YS, Witte BI, van Nieuwkerk CM, Mulder CJ, Bouma G, de Man RA; Dutch Autoimmune Hepatitis Study Group: Seroprevalence of hepatitis E virus in autoimmune hepatitis patients in the Netherlands. J Gastrointestin Liver Dis 2016;25:9-13.
45.
Vento S, Guella L, Mirandola F, Cainelli F, Di Perri G, Solbiati M, Ferraro T, Concia E: Epstein-Barr virus as a trigger for autoimmune hepatitis in susceptible individuals. Lancet 1995;346:608-609.
46.
Manns MP: Viruses and autoimmune liver disease. Intervirology 1993;35:108-115.
47.
Gatselis NK, Zachou K, Koukoulis GK, Dalekos GN: Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics. World J Gastroenterol 2015;21:60-83.
48.
Castiella A, Zapata E, Lucena MI, Andrade RJ: Drug-induced autoimmune liver disease: a diagnostic dilemma of an increasingly reported disease. World J Hepatol 2014;6:160-168.
49.
Björnsson E, Talwalkar J, Treeprasertsuk S, Kamath PS, Takahashi N, Sanderson S, Neuhauser M, Lindor K: Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010;51:2040-2048.
50.
Czaja AJ: Drug-induced autoimmune-like hepatitis. Dig Dis Sci 2011;56:958-976.
51.
Abe M, Furukawa S, Takayama S, Michitaka K, Minami H, Yamamoto K, Horiike N, Onji M: Drug-induced hepatitis with autoimmune features during minocycline therapy. Intern Med 2003;42:48-52.
52.
Kamiyama T, Nouchi T, Kojima S, Murata N, Ikeda T, Sato C: Autoimmune hepatitis triggered by administration of an herbal medicine. Am J Gastroenterol 1997;92:703-704.
53.
Sugimoto K, Ito T, Yamamoto N, Shiraki K: Seven cases of autoimmune hepatitis that developed after drug-induced liver injury. Hepatology 2011;54:1892-1893.
54.
Hisamochi A, Kage M, Ide T, Arinaga-Hino T, Amano K, Kuwahara R, Ogata K, Miyajima I, Kumashiro R, Sata M, Torimura T: An analysis of drug-induced liver injury, which showed histological findings similar to autoimmune hepatitis. J Gastroenterol 2016;51:597-607.
55.
Oh HJ, Mok YM, Baek MS, Lee JK, Seo BS, Kim TH, Choi KH, Hwang IK, Ra JE, Oh YR, Kim YS, Cho EY, Kim HC, Sohn YW: Co- development of autoimmune hepatitis and Sjögren's syndrome triggered by the administration of herbal medicines. Clin Mol Hepatol 2013;19:305-308.
56.
World Health Organization: National Policy on Traditional Medicine and Regulation of Herbal Medicines - Report of a WHO Global Survey. Geneva, World Health Organization, 2005.
57.
Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WG, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston AL, Fainboim L, Heathcote J, Homberg JC, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RN, Maddrey WC, Manns MP, McFarlane IG, Meyer zum Büschenfelde KH, Mieli-Vergani G, Nakanuma Y, Nishioka M, Penner E, Porta G, Portmann BC, Reed WD, Rodes J, Schalm SW, Scheuer PJ, Schrumpf E, Seki T, Toda G, Tsuji T, Tygstrup N, Vergani D, Zeniya M: International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-938.
58.
Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, Bittencourt PL, Porta G, Boberg KM, Hofer H, Bianchi FB, Shibata M, Schramm C, Eisenmann de Torres B, Galle PR, McFarlane I, Dienes HP, Lohse AW; International Autoimmune Hepatitis Group: Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48:169-176.
59.
Toda G: Diagnosis guide for autoimmune hepatitis in Japan, 1996 (in Japanese). Kanzo 1996;37:298-300.
60.
Onji M, Zeniya M, Yamamoto K, Tsubouchi H: Autoimmune hepatitis: diagnosis and treatment guide in Japan, 2013. Hepatol Res 2014;44:368-370.
61.
Migita K, Jiuchi Y, Furukawa H, Nakamura M, Komori A, Yasunami M, Kozuru H, Abiru S, Yamasaki K, Nagaoka S, Hashimoto S, Bekki S, Yoshizawa K, Shimada M, Kouno H, Kamitsukasa H, Komatsu T, Hijioka T, Nakamuta M, Naganuma A, Yamashita H, Nishimura H, Ohta H, Nakamura Y, Ario K, Oohara Y, Sugi K, Tomizawa M, Sato T, Takahashi H, Muro T, Makita F, Mita E, Sakai H, Yatsuhashi H: Lack of association between the CARD10 rs6000782 polymorphism and type 1 autoimmune hepatitis in a Japanese population. BMC Res Notes 2015;8:777.
62.
Ohira H, Abe K, Takahashi A, Watanabe H: Autoimmune hepatitis: recent advances in the pathogenesis and new diagnostic guidelines in Japan. Intern Med 2015;54:1323-1328.
63.
Miyake Y, Iwasaki Y, Kobashi H, Yasunaka T, Ikeda F, Takaki A, Okamoto R, Takaguchi K, Ikeda H, Makino Y, Ando M, Sakaguchi K, Yamamoto K: Efficacy of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis. Hepatol Int 2009;3:556-562.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.